Cancer
Roche’s Zelboraf rejected by NICE
June 15, 2012Sales and Marketing Cancer, Dillon, NICE, Roche, Zelboraf, melanoma
NICE is not recommending Roche’s targeted melanoma pill Zelboraf because of its high cost and uncertainties over its survival benefit. …
William Kaelin Jr elected to Lilly board
June 6, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Kaelin, lilly
Eli Lilly has elected William Kaelin Jr to its board of directors. Dr Kaelin, 54, is a Professor in the Department of …
Herceptin successor impresses at ASCO
June 6, 2012Research and Development, Sales and Marketing ASCO, Cancer, EMILIA, FDA, Roche, T-DM1
Roche’s new ‘smart bomb’ breast cancer drug T-DM1 has impressed at this year’s ASCO conference in Chicago. The trial showed it …
Cancer Drugs Fund ‘the wrong choice’ for Wales
May 29, 2012Sales and Marketing CDF, Cancer, NHS, Wales, Welsh
The Welsh health minister Lesley Griffiths has said that a Cancer Drugs Fund is ‘not the right course’ for Wales. …
Scottish watchdog rejects Yervoy
May 14, 2012Sales and Marketing BMS, Cancer, NICE, SMC, Yervoy, melanoma
The Scottish Medicines Consortium is not recommending Bristol-Myers Squibb’s melanoma treatment Yervoy. The SMC said that Yervoy (ipilimumab), which has …
UK government launches lung cancer awareness campaign
May 8, 2012Medical Communications Cancer, UK, government, lung
The UK government has launched a new lung cancer awareness campaign backed by a number of celebrities. Ricky Gervais and …
GSK signs deal with academics
May 4, 2012Research and Development, Sales and Marketing Cancer, GSK, PROTAC, Yale, academia
GlaxoSmithKline has forged another link with academia, signing a deal with Yale University to design a potential new class of …
FDA approves GSK’s Votrient for new licence
April 30, 2012Sales and Marketing Cancer, FDA Approval, GSK, Votrient
The FDA has approved GlaxoSmithKline’s cancer pill Votrient for the treatment of a rare group of cancers – but has …
New data shows Herceptin’s ability to increase survival
April 24, 2012Research and Development, Sales and Marketing Cancer, Cochrane, Herceptin, Roche, breast
A new review of Roche’s breast cancer drug Herceptin has confirmed its ability to increase overall survival, but concerns remain …
Government to speed up access to new cancer drugs
April 24, 2012Sales and Marketing CDF, Cancer, Roche, UK, avastin, government, sha
Access to England’s Cancer Drugs Fund will be speeded up, ministers have confirmed. Currently, it can take a number of …
Merck does cancer drug deal with Endocyte
April 17, 2012Research and Development, Sales and Marketing Cancer, Endocyte, Merck, NSCLC, vintafolide
Merck is to pay $120 million to US biopharma company Endocyte as part of a deal to develop and commercialise …
UK government invests in new radiotherapy treatment
April 16, 2012Sales and Marketing Cancer, Photon beam therapy, Proton beam therapy, prostate cancer, radiotherapy
The government is to invest £250 million in a cutting-edge radiotherapy treatment that should benefit 1,500 cancer patients in the …
Access to new cancer drugs limited in Brazil and Mexico
April 13, 2012Sales and Marketing Brazil, Cancer, Mexico, avastin, emerging markets
Between one-quarter and one-third of patients in Brazil and Mexico who are eligible for treatment with new cancer drugs do …
Bayer cancer drug meets Phase III goal
April 3, 2012Research and Development, Sales and Marketing Bayer, Cancer, Glivec, Novartis, phase III, regorafenib
Bayer’s stomach cancer pill regorafenib has significantly improved progression free survival in late-stage patients. Results from the Phase III trial …
Photodynamic treatment for HPV shows potential
March 15, 2012Research and Development Cancer, GE Healthcare, HPV, Photocure, ipsen, oncologly
A new photodynamic therapy treatment for human papilloma virus (HPV) associated diseases of the cervix has shown potential in a …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
